WebFeb 16, 2024 · At this valuation, a 29.9% share stake in Evidian would cost 1.2 billion euros. Atos’ market capitalisation is close to 1.3 billion. The company declined to comment. Atos rejected last September an unsolicited offer from rival onepoint and UK private equity fund ICG at an indicative enterprise value of 4.2 billion euros ($4.1 billion). Web4. 22. Target $ 2.78 Atossa Therapeutics (ATOS) said Wednesday it has completed enrollment in part B of its phase 1/2a trial of drug candidate AT-H201 in Australia. AT-H201 is being developed as an inhalation therapy for moderately to severely ill hospitalized COVID-19 patients and for "long-haul" patients with post-inAtossa Therapeutics (ATOS ...
Atos Company Profile - Office Locations, Competitors, Revenue …
WebFeb 16, 2024 · Atos' market capitalisation is close to 1.3 billion. The company declined to comment. Atos rejected last September an unsolicited offer from rival onepoint and UK private equity fund ICG at an ... WebApr 6, 2024 · Atos has 5 employees across 187 locations and €11.34 b in annual revenue in FY 2024. See insights on Atos including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. ... Market Capitalization. €1.2 B. 2024-04-06. Revenue. €11.3 B. FY, 2024. Atos Summary. Company summary. shera browser
Atos (ATO.PA) - Market capitalization
WebMarket capitalization of Atossa Therapeutics (ATOS) Market cap: $91.72 Million As of April 2024 Atossa Therapeutics has a market cap of $91.72 Million.This makes Atossa … WebApr 11, 2024 · The Atossa Genetics stock price gained 4.88% on the last trading day (Tuesday, 11th Apr 2024), rising from $0.706 to $0.740. During the last trading day the stock fluctuated 7.25% from a day low at $0.690 … Web26 rows · Apr 6, 2024 · Market Capitalization Definition. Market Capitalization … springfield senior olympics dinner